Quantitative determination of olanzapine in rat brain tissue by high-performance liquid chromatography with electrochemical detection

被引:27
作者
Bao, JQ [1 ]
Potts, BD [1 ]
机构
[1] Eli Lilly & Co, Dept Drug Disposit, Indianapolis, IN 46285 USA
来源
JOURNAL OF CHROMATOGRAPHY B | 2001年 / 752卷 / 01期
关键词
olanzapine;
D O I
10.1016/S0378-4347(00)00518-1
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
A sensitive assay was developed for the measurement of olanzapine in rat brain tissue using HPLC with electrochemical detection. The assay has a lower limit of quantitation of 0.5 ng/ml in tissue homogenate and utilizes a liquid-liquid extraction followed by reversed-phase HPLC for the quantitative analysis of olanzapine. The method provided a linear response for olanzapine over a concentration range of 0.5-100 ng/ml with a coefficient of determination (r(2)) greater than 0.9995. The extraction efficiencies of olanzapine and internal standard (LY170158) were greater than 82% in brain tissue. The intra-assay and inter-assay relative errors ranged from -5.38 to 17.60% and -3.25 to 10.53%, respectively. The intra-assay and inter-assay RSD values were in the range of 1.12 to 6.96% and 3.78 to 6.68%. Long-term stability studies showed that brain tissue homogenate samples spiked with olanzapine and internal standard are stable at -70 degreesC for at least 110 days. However, a room temperature stability study showed that olanzapine was not stable in brain homogenate if the sample was exposed at 25 degreesC longer than 2 h. This method has been used for the study of the disposition and pharmacokinetics of olanzapine in male Sprague-Dawley rats. (C) 2001 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:61 / 67
页数:7
相关论文
共 15 条
[1]  
AASSAHUN K, 1996, DRUG METAB DISPOS, V25, P81
[2]   Plasma level monitoring of olanzapine in patients with schizophrenia: Determination by high-performance liquid chromatography with electrochemical detection [J].
Aravagiri, M ;
Ames, D ;
Wirshing, WC ;
Marder, SR .
THERAPEUTIC DRUG MONITORING, 1997, 19 (03) :307-313
[3]   Olanzapine versus placebo and haloperidol - Acute phase results of the North American double-blind olanzapine trial [J].
Beasley, CM ;
Tollefson, G ;
Tran, P ;
Satterlee, W ;
Sanger, T ;
Hamilton, S ;
Fabre, L ;
Small, J ;
Ereshefsky, L ;
True, J ;
Nemeroff, C ;
Risch, SC ;
Perry, PJ ;
Potkin, SG ;
Borison, RL ;
James, S ;
Meltzer, HY ;
Iqbal, N ;
Fann, WE ;
Gewirtz, GR ;
Landbloom, R ;
RoyByrne, PP ;
Tuason, VB ;
Carman, JS ;
Stokes, PE ;
Williams, R ;
Ancill, RJ ;
MacEwan, GW ;
Gujavarty, KS ;
Jones, B ;
Lohr, JB .
NEUROPSYCHOPHARMACOLOGY, 1996, 14 (02) :111-123
[4]  
Berna M, 1998, J MASS SPECTROM, V33, P1003, DOI 10.1002/(SICI)1096-9888(1998100)33:10<1003::AID-JMS716>3.0.CO
[5]  
2-P
[6]   Antagonism by olanzapine of dopamine D1, serotonin2, muscarinic, histamine H1 and α1,-adrenergic receptors in vitro [J].
Bymaster, FP ;
Nelson, DL ;
DeLapp, NW ;
Falcone, JF ;
Eckols, K ;
Truex, LL ;
Foreman, MM ;
Lucaites, VL ;
Calligaro, DO .
SCHIZOPHRENIA RESEARCH, 1999, 37 (01) :107-122
[7]   The synthesis and biological activity of some known and putative metabolites of the atypical antipsychotic agent olanzapine (LY170053) [J].
Calligaro, DO ;
Fairhurst, J ;
Hotten, TM ;
Moore, NA ;
Tupper, DE .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1997, 7 (01) :25-30
[8]   ANALYSIS OF OLANZAPINE IN HUMAN PLASMA UTILIZING REVERSED-PHASE HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH ELECTROCHEMICAL DETECTION [J].
CATLOW, JT ;
BARTON, RD ;
CLEMENS, M ;
GILLESPIE, TA ;
GOODWIN, M ;
SWANSON, SP .
JOURNAL OF CHROMATOGRAPHY B-BIOMEDICAL APPLICATIONS, 1995, 668 (01) :85-90
[9]  
CHOU JA, 1996, J PHARM BIOMED ANAL, V14, P609
[10]   VAPOR-PHASE SILYLATION OF LABORATORY GLASSWARE [J].
FENIMORE, DC ;
DAVIS, CM ;
WHITFORD, JH ;
HARRINGTON, CA .
ANALYTICAL CHEMISTRY, 1976, 48 (14) :2289-2290